Neratinib was assessed in the first line metastatic setting in the phase II NEfERT trial, where 479 patients with HER2-positive ABC were randomised to receive paclitaxel plus either neratinib or trastuzumab. Here, ERBB2 is linked to aneurysmal bone cyst.